Evolus (EOLS) | Stock Overview & Key Data
Evolus Performance Comparison
Stock Range
Today's Range
Low: $8.65
High: $9.18
on August 1, 2025
52 Week Range
Low: $8.65
High: $17.82
on August 1, 2025
on October 14, 2024
All-Time High: $39.50 on June 4, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$590.0M
EPS
-0.89
P/E Ratio (TTM)
-11.30
Forward P/E
45.75
P/B Ratio
-88.25
PEG Ratio
45.75
Div. Yield
N/A
ROE
-949.46%
Beta
0.976
Debt to Equity
-19.72
Financial Highlights
Profitability
Gross Margin
68.09%
Operating Margin
-19.00%
Profit Margin
-20.40%
Returns and Earnings
Return on Assets (TTM)
-9.36%
Return on Equity (TTM)
-949.46%
EBITDA
$-27.5M
Net Income (TTM)
$-56.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$4.34
Quarterly Revenue Growth (YoY)
15.50%
Quarterly Earnings Growth (YoY)
15.49%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Evolus EOLS | 589.95M Small-cap | -3.99% | -0.54% | -22.46% | -29.51% | -17.64% | -33.98% | -2.66% | 160.68% |
| Zoetis ZTS | 67.73B Large-cap | -3.12% | -7.42% | -5.31% | -14.28% | -9.37% | -18.39% | -15.59% | -7.24% |
| Haleon Plc - ADR HLN | 43.39B Large-cap | -2.23% | -6.67% | -6.49% | 1.90% | 2.33% | 0.31% | 29.32% | 30.36% |
| Supernus SUPN | 1.99B Small-cap | 5.75% | 11.60% | 9.43% | -4.95% | -2.53% | 23.38% | 10.42% | 53.86% |
| BGM BGM | 1.73B Small-cap | -17.70% | -16.67% | -23.89% | -14.00% | -3.80% | 43.09% | 18.62% | -80.34% |
| BioCryst BCRX | 1.66B Small-cap | -7.02% | -11.67% | -8.73% | 4.33% | 1.53% | 13.25% | -43.42% | 100.25% |
Ownership & Short Interest
Insider Ownership
5.46%
Institutional Ownership
85.47%
Shares Short
13M
Short Ratio
14.11
Short % of Shares Outstanding
20.01%
Average 10-Day Volume
1M
Average 90-Day Volume
923K
Evolus Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Evolus would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is EOLS's 52-week high and low?
- In the last 52 weeks, Evolus reached a high of $17.82 (on October 14, 2024) and a low of $8.65 (on August 1, 2025).
- What is the market cap and P/E ratio for EOLS?
- Curious about Evolus's size and valuation? Its market capitalization stands at 589.95M. When it comes to valuation, the P/E ratio (trailing twelve months) is -11.30, and the forward P/E (looking ahead) is 45.75.
- Does EOLS pay dividends? If so, what's the yield?
- As for dividends, Evolus isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Evolus's main competitors or similar companies to consider before investing?
When looking at Evolus, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS67.73B Healthcare Drug Manufacturers - Specialty & Generic -18.39% -15.59% Haleon Plc - ADR
HLN43.39B Healthcare Drug Manufacturers - Specialty & Generic 0.31% 29.32% Supernus
SUPN1.99B Healthcare Drug Manufacturers - Specialty & Generic 23.38% 10.42% BGM
BGM1.73B Healthcare Drug Manufacturers - Specialty & Generic 43.09% 18.62% BioCryst
BCRX1.66B Healthcare Drug Manufacturers - Specialty & Generic 13.25% -43.42% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Evolus Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Evolus's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -949.46%, the Debt to Equity ratio from the most recent quarter is -19.72, and its Gross Profit Margin stands at 68.09%.
- What is the recent revenue and earnings growth for EOLS?
- Looking at Evolus's growth, its revenue over the trailing twelve months (TTM) was $275M. Compared to the same quarter last year (YoY), quarterly revenue grew by 15.50%, and quarterly earnings saw a YoY growth of 15.49%.
- How much of EOLS stock is held by insiders and institutions?
- Wondering who owns Evolus stock? Company insiders (like executives and directors) hold about 5.46% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 85.47%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.